OMCL

EX-99.1

2 exhibit991q3-26.htm

EX-99.1

Document

Exhibit 99.1

Contact:Omnicell, Inc.

David Unger4220 North Freeway

Vice President, Investor RelationsFort Worth, TX 76137

ir@omnicell.com

Omnicell Announces Third Quarter 2026 Financial Results

Omnicell delivers solid third quarter 2026 financial results

Updates full year 2026 guidance

FORT WORTH, Texas -- October 29, 2026 -- Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” or the “Company”), a healthcare technology leader focused on advancing autonomous medication management, today reported financial results for the third quarter ended September 30, 2026.

Third quarter results reflected continued execution across the business, supported by demand for Omnicell’s connected device portfolio, favorable product and service margins and disciplined cost management. Our business performed well during the quarter, with revenue and profitability both coming in above the high end of our previously provided guidance range, and we continue to see healthcare providers prioritize solutions that are designed to improve operational efficiency, optimize medication workflows, and help address ongoing workforce challenges.

“We delivered solid third quarter results and continued to execute against our strategic priorities,” said Randall A. Lipps, chairman, chief executive officer, and founder of Omnicell. “We believe our performance reflects the discipline we have built into the business throughout the year, combined with continued customer interest in solutions that are designed to improve efficiency, safety, and workforce productivity across medication management.”

“At the same time, we continue to see strong momentum with our next-generation platform, backed by a growing pipeline,” Lipps added. “Customers are validating the potential value of combining Titan XT with OmniSphere, our cloud-native platform, intended to improve productivity, efficiency, and workflow reliability. As we see health systems seek greater visibility and connectivity across the medication-use process, we believe Omnicell Titan XT and OmniSphere position us to capitalize on a significant long-term opportunity we see in autonomous medication management.”

Financial Results

Total revenues for the third quarter of 2026 were $308 million, down $3 million, or 1%, from the third quarter of 2025.

Total GAAP net income for the third quarter of 2026 was $11 million, or $0.24 per diluted share. This compares to GAAP net income of $5 million, or $0.12 per diluted share, for the third quarter of 2025.

Total non-GAAP net income for the third quarter of 2026 was $27 million, or $0.58 per diluted share. This compares to non-GAAP net income of $24 million, or $0.51 per diluted share, for the third quarter of 2025.

Total non-GAAP EBITDA for the third quarter of 2026 was $45 million. This compares to non-GAAP EBITDA of $41 million for the third quarter of 2025.

Balance Sheet

As of September 30, 2026, Omnicell’s balance sheet reflected cash and cash equivalents of $315 million, total debt (net of unamortized debt issuance costs) of $169 million, and total assets of $2.1 billion. Cash flows provided by operating activities in the

1

third quarter of 2026 totaled $33 million. This compares to cash flows provided by operating activities totaling $28 million in the third quarter of 2025.

As of September 30, 2026, the Company had $350 million of availability under its revolving credit facility with no outstanding balance.

Corporate Highlights

•Over 200 healthcare leaders and industry experts joined Omnicell for the sixth annual Illuminate, a virtual education and best practice sharing event. Panel discussions focused on real-world experiences building connected, intelligent medication management strategies that are designed to help drive meaningful clinical, operational, and financial outcomes.

•Issued the 2025 Environmental, Social, and Governance (ESG) Report, which reflects Omnicell’s ongoing commitment to ESG principles. Guided by innovation, the Report highlights the Company’s continuous focus on advancing autonomous medication management while supporting a more sustainable and patient-centered healthcare ecosystem.

2026 Guidance

The table below summarizes Omnicell’s fourth quarter and updated full year 2026 guidance. Given our strong third quarter 2026 profitability performance and continued focus on disciplined execution, we are increasing our full year 2026 non-GAAP EBITDA and non-GAAP earnings per share guidance ranges. In addition, as we are through the first three quarters of the year, we are tightening our full year 2026 total, product, and service revenues guidance ranges. We are also tightening our full year 2026 annual recurring revenue guidance range, with the low end unchanged, reflecting our increased visibility into the business as we approach year end. We are reiterating our product bookings guidance range, which continues to reflect our current assessment of the range of potenti

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.e618d017.1785675296.3db76a14

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

EX-99.1

2 exhibit991q1-26.htm

EX-99.1

Document

Exhibit 99.1

Contact:Omnicell, Inc.

Investor Relations4220 North Freeway

Investor.Relations@omnicell.comFort Worth, TX 76137

Omnicell Announces First Quarter 2026 Financial Results

Omnicell delivers strong first quarter 2026 financial results

Raises full year 2026 non-GAAP EBITDA and non-GAAP EPS guidance

Customer engagement underway for Omnicell Titan XT and OmniSphere

FORT WORTH, Texas -- April 28, 2026 -- Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” or the “Company”), a leading healthcare technology provider focused on empowering autonomous medication management, today reported financial results for the first quarter ended March 31, 2026.

First quarter results reflected strong execution across the business, supported by demand for Omnicell’s connected device portfolio and solid performance across the Company’s core points of care solutions. We believe that performance during the quarter underscores the durability of Omnicell’s model, supported by disciplined cost management which contributed to improved profitability.

“We delivered a strong start to 2026, driven by solid execution and sustained demand for our points of care solutions,” said Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell. “As care environments continue to become more complex, we see that health systems are prioritizing reliability, efficiency, and standardization in medication workflows. During the quarter, we continued to advance solutions designed to support health systems as they manage increasingly complex medication workflows, optimize the medication supply chain, and improve operational efficiency while enhancing both the caregiver and patient experience.”

“At the same time, we advanced the next phase of our platform evolution,” Lipps added. “Following the introduction of Omnicell Titan XT at ASHP, customer engagement is underway as health systems begin incorporating the platform into longer-term capital planning cycles. OmniSphere continues to mature as our enterprise, system-wide, cloud-native platform, built to enable greater visibility, analytics, and workflow intelligence across medication management. We believe Omnicell Titan XT and OmniSphere represent a meaningful long-term opportunity and provide a strong foundation for enterprise-wide intelligence, workflow optimization, and durable growth as adoption scales over time.”

Financial Results

Total revenues for the first quarter of 2026 were $310 million, up $40 million, or 15%, from the first quarter of 2025. The year-over-year increase in total revenues was driven by strength in our connected devices offerings, as well as increases in technical services, SaaS and Expert Services, and consumables revenues.

Total GAAP net income for the first quarter of 2026 was $11 million, or $0.25 per diluted share. This compares to GAAP net loss of $7 million, or $0.15 per diluted share, for the first quarter of 2025.

Total non-GAAP net income for the first quarter of 2026 was $25 million, or $0.55 per diluted share. This compares to non-GAAP net income of $12 million, or $0.26 per diluted share, for the first quarter of 2025.

Total non-GAAP EBITDA for the first quarter of 2026 was $45 million. This compares to non-GAAP EBITDA of $24 million for the first quarter of 2025.

1

Balance Sheet

As of March 31, 2026, Omnicell’s balance sheet reflected cash and cash equivalents of $239 million, total debt (net of unamortized debt issuance costs) of $168 million, and total assets of $2.0 billion. Cash flows provided by operating activities in the first quarter of 2026 totaled $55 million. This compares to cash flows provided by operating activities totaling $26 million in the first quarter of 2025.

As of March 31, 2026, the Company had $350 million of availability under its revolving credit facility with no outstanding balance.

Corporate Highlights

•The Omnicell Titan XT Automated Dispensing System and OmniSphere were showcased at the American Organization for Nursing Leadership (AONL) 2026 Annual Meeting, where nursing leaders had the opportunity to explore this next generation technology and how it is expected to minimize the time nurses spend locating medications and enable safer medication administration.

•Omnicell connected with global pharmacy leaders at the 30th EAHP Congress, the annual gathering for the European Association of Hospital Pharmacists to showcase how intelligence-driven solutions are transforming medication and supply management.

•In March 2026, the Company launched the Omnicell Customer Community, a new virtual networking space that provides a forum for customers to collaborate, share insights, and gain peer-to-peer best practices.

2026 Guidance

The table below summarizes Omnicell’s second quarter and updated full year 2026 guidance. Given the strength of our first quarter 2026 profitability performance and ongoing focus on spend discipline, we are increasi